Oral Sessions (Day1, Day2, Day3)
Poster Presentations (Day1, Day2, Day3)
Poster Presentations
- Day 3, June 24（Fri.） Room P (501, 502 and 503)
-
3P-26 PDF
Investigation of Metabolite Markers for Evaluating Signs of Early Phase Toxicity of Anticancer Agent Treatment Based on Inflammatory Markers S100A8/A9
Anticancer agent-induced toxicity is strongly related to tissue damages/inflammatory reactions. S100 calcium-binding proteins A8/A9 (S100A8/A9) accumulate at inflammatory sites and are known to be related to tissue damage/inflammation; however, their response to drug toxicity has not been reported. Herein, we investigated the effects of anticancer agents (doxorubicin, cisplatin, and docetaxel) on S100A8/A9 gene expression profiles in representative four tissues (heart, kidney, liver, and lung) in normal C57BL/6J mice. Both S100A8/A9 expression was elevated in four tissues within 48 h after dosing of the three anticancer agents under toxicity-inducing conditions. Metabolomic analysis revealed that some metabolites showed temporal patterns similar to that of S100A8/A9 expression. The amounts of fumarate (doxorubicin-treated heart), tyrosine (cisplatin-treated kidney), acetylcarnosine (doxorubicin-treated liver), and 2-phosphoglycerate (docetaxel-treated lung) showed similar patterns to that of S100A8/A9 expression. These results suggest that combining S100A8/A9 expression patterns and metabolic alterations would be useful strategy for evaluating signs of possible inflammation and tissue damage in the early phase after administration of anticancer agents.